Comment je traite... les cancers localises de l'oesophage. Etat actuel des donnees et strategie therapeutique. 1ere partie : le point sur les approches chirurgicales et non chirurgicales.
VAN DAELE, Daniel; Honoré, Pierre; COLLIGNON, Joëlleet al.
2017 • In Revue Médicale de Liège, 72 (2), p. 58-63
[en] Esophageal cancers represent a highly heterogeneous entity mixing two different tumour types : AdenoCarcinoma (ADC) and Squamous Cell Carcinoma (SSC). Developing in the same organ, they are very often considered as a unique pathology and, consequently, the same therapeutic strategy is indiscriminately applied. Esophageal cancer treatments are particularly complex and require a multidisciplinary approach. Despite impressive advances in the tumour statidifaction, surgery, radiotherapy and chemotherapy, the overall prognosis remains grim even at an early stage of the disease. In order to improve the treatment of esophageal cancers and the patientaeuros survival, we need to consider that ADC and SCC represent two different pathologies requiring specific therapeutic strategies. This review in two parts will present recent data from clinical trials under the scope of tumour histology to set up dedicated therapeutic strategies. In this first part, we explain the restricted role of surgical resection, the prognostic factors and the results of exclusive combined chemotherapy and radiation in localized esophageal cancer.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
VAN DAELE, Daniel ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Honoré, Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Chirurgicale abdominale
COLLIGNON, Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > Service d'oncologie médicale
POLUS, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
LOLY, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
MUTIJIMA NZARAMBA, Eugène ; Centre Hospitalier Universitaire de Liège - CHU > Service d'anatomie et cytologie pathologiques
De Roover, Arnaud ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Coucke, Philippe ; Université de Liège - ULiège > Département des sciences cliniques > Radiothérapie
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Martinive, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Language :
French
Title :
Comment je traite... les cancers localises de l'oesophage. Etat actuel des donnees et strategie therapeutique. 1ere partie : le point sur les approches chirurgicales et non chirurgicales.
Alternative titles :
[en] Comprehensive therapeutic strategy for localized esophageal cancer
Publication date :
2017
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Cancer incidence in Belgium 2008.-Belgian Cancer Registry, 36-41.
Siegel R, Ma J, Zou Z, Jemal A et al.-Cancer statistics, 2014. CA Cancer J Clin, 2014, 64, 9-29.
SEER Stat Fact Sheets: Esophagus; Survival and Stage.-seer.cancer.gov/statfacts/html/esoph. html#survival-Consultation du 1 mai 2012.
Mayer RJ, Venook AP, Diller H et al.-Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol, 2014, 32, 1521-1530.
Blot WJ, Devesa SS, Kneller RW et al.-Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA, 1991, 265, 1287-1289.
Siewert JR, Feith M, Stein HJ et al.-Biologic and clinical variations of adenocarcinoma at the esophagogastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol, 2005, 90, 139-146.
Siewert JR, Ott K.-Are squamous and adenocarcinomas of the esophagus the same disease ? Semin Radiat Oncol, 2007,17, 38-44.
Mariette C, Finzi L, Piessen G et al.-Esophageal carcinoma : prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg, 2005, 29, 39-45.
Lieberman MD, Shriver CD, Bleckner S et al.-Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg, 1995, 109, 130-138.
Siewert JR, Stein HJ, Feith M et al.-Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg, 2001, 234, 360-367.
Hölscher AH, Bollschweiler E, Schneider et al.-Prognosis of early esophageal cancer. Comparison between adeno-and squamous cell carcinoma. Cancer, 1995, 76, 178-186.
Devesa SS, Blot WJ, Fraumeni JF Jr.-Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer, 1998, 83, 2049-2053.
Vial M, Grande L, Pera M.-Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results. Cancer Res, 2010, 182, 1-17.
Hansen S, Wiig JN, Giercksky KE et al.-Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer, 1997, 71, 340-344.
Hvid-Jensen F, Pedersen L, Drewes AM et al.-Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med, 2011, 365, 1375-1383.
Herskovic A, Martz K, al-Sarraf M et al.-Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 1992, 326, 1593-1598.
Cooper JS, Guo MD, Herskovic A et al.-Chemoradiotherapy of locally advanced esophageal cancer : long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 1999, 281, 1623-1627.
Kelsen DP, Ginsberg R, Pajak TF et al.-Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med, 1998, 339, 1979-1984.
van Hagen P, Hulshof MC, van Lanschot JJ et al.-Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366, 2074-2084.
Mariette C, Dahan L, Mornex F et al.-Surgery alone versus chemoradiotherapy followed by surgery for stage i and ii esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol, 2014, 32, 2416-2422.
O'Reilly S, Forastiere AA.-Is surgery necessary with multimodality treatment of oesophageal cancer. Ann Oncol, 1995, 6, 519-521.
Bosset JF, Gignoux M, Triboulet JP et al.-Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med, 1997, 337, 161-167.
Rice TW, Rusch VW, Apperson-Hansen C et al.-Worldwide esophageal cancer collaboration. Dis Esophagus, 2009, 22, 1-8.
Mariette C, Fabre S, Balon JM et al.-Factors predictive of complete resection of operable esophageal cancer: review of 746 patients. Gastroenterol Clin Biol, 2002, 6, 454-462.
Verhoef C, van de Weyer R, Schaapveld M et al.-Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists. Ann Surg Oncol, 2007, 14, 1678-1687.
Earlam R, Cunha-Melo JR.-Oesophogeal squamous cell carcinomas: II. A critical view of radiotherapy. Br J Surg, 1980, 67, 457-461.
Minsky BD, Pajak TF, Ginsberg RJ et al.-INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol, 2002, 20, 1167-1174.
Wong R, Malthaner R.-Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev, 2001, CD002092.
Shioyama Y, Nakamura K, Sasaki T et al.-Clinical results of radiation therapy for stage I esophageal cancer: a single institutional experience. Am J Clin Oncol, 2005, 28, 75-80.
Yu J, Ren R, Sun X et al.-A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer (abstract). J Clin Oncol, 2006, 24, 181s.
Conroy T, Galais MP, Raoul JL et al.-Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised phase 2/3 trial. Lancet Oncology, 2014, 15, 305-314.
Crosby T, Hurt CN, Falf S et al.-Chemoradiotherapy with or without Cetuximab in patients with oesophageal cancer (SCOPE1): a multicenter, phase 2/3 randomised trial. Lancet Oncology, 2013, 14, 627-637.
